USP1
39 programs · 38 companies
Programs
39
Companies
38
Active Trials
28
Targeting USP1
| Drug | Company | Phase | MOA | Indications |
|---|---|---|---|---|
| ABB-2476 | AbbVie | Phase 1/2 | GAHeart Failure | |
| Tezesotorasib | Enliven | Phase 2 | Atopic DermHS | |
| ETN-5063 | 89bio | Phase 1/2 | CLLMDS | |
| MD-IIT-621 | MD Anderson | Phase 2/3 | CRC | |
| GUS-IIT-951 | Gustave Roussy | Approved | LGS | |
| SWO-IIT-148 | SWOG | Approved | HS | |
| UCS-IIT-951 | UCSF | Phase 2 | GA | |
| MIR-7357 | Mirati (BMS) | Preclinical | Gastric CaAngelman | |
| SCO-5362 | Scorpion | NDA/BLA | CRCMDD | |
| Zanutuximab | Asklepios Bio | Phase 2/3 | Asthma | |
| Tixafutibatinib | ProKidney | Phase 1/2 | Parkinson'sCervical Ca | |
| Teratapinarof | Aravive | Phase 3 | RettOvarian Ca | |
| Pexasacituzumab | Genor BioPharma | Preclinical | LGS | |
| Talafotisoran | Principia (Sanofi) | Phase 1 | Melanoma | |
| Liravorutinib | Retrophin (Zevra) | Preclinical | GISTPBC | |
| BIO-7835 | BioNova | Phase 1/2 | OCDIgAN | |
| Zenoglumide | Yuhan Corp | Phase 2 | RCCLN | |
| KAR-9558 | Kartos | Approved | HS | |
| Niranaritide | Ajax Ther | Phase 2/3 | SMA | |
| MIR-4070 | Mirum Pharma | Phase 1/2 | Huntington'sParkinson's | |
| Rimacilimab | Homology Med | Phase 3 | PompeALL | |
| Fixatapinarof | Maplewood Bio | Phase 2 | DLBCLSchizophrenia | |
| Zanuderotide | Modalis Ther | Phase 1 | PTSD | |
| Lirazanubrutinib | Zydus Life | Phase 1 | PTSD | |
| Niratenlimab | Circassia | Phase 1 | RettHS | |
| DBV-5518 | DBV Technologies | Phase 1 | CRCFL | |
| 414-5700 | TaiMed Bio | Preclinical | MM | |
| PHL-685 | Philogen | Approved | CholangiocarcinomaEwing Sarcoma | |
| DIV-5162 | Divi's Laboratories | Preclinical | MyelofibrosisMS | |
| BIO-IIT-514 | Bio Farma | Approved | Ewing Sarcoma | |
| Elrabrutinib | Siam Bioscience | Phase 2 | Gastric CaCervical Ca | |
| Adagranesiran | Abdi Ibrahim | Phase 2 | LGS | |
| RIK-IIT-812 | RIKEN | Phase 2 | Celiac | |
| RIK-IIT-251 | RIKEN | Phase 1/2 | HS | |
| SCI-9998 | Scientus Pharma | Approved | Prostate Ca | |
| Polacilimab | Bioceres Crop | NDA/BLA | CFRCC | |
| Rimatenlimab | Agilent Technologies | Phase 2 | Cervical Ca | |
| Gozeinavolisib | IDEXX Laboratories | Phase 2/3 | Cholangiocarcinoma | |
| DYN-8432 | Dyne Therapeutics | Phase 1/2 | CholangiocarcinomaMDD |